GHIT Fund   [to 3 June 2017]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical ·  2017.06.01      Press Room
GHIT Fund Secures Commitments of Over US$200 Million to its Replenishment for the Acceleration of Japanese Innovation for Infectious Diseases of the Developing World
This announcement demonstrates the continued leadership and commitment of the Government of Japan, leading life sciences companies, international foundations and other partners to combat neglected diseases; with this replenishment, which marks a doubling of previous commitments, GHIT will accelerate and expand its development of new tools while ensuring they are accessible and delivered to the world’s most vulnerable
TOKYO, JAPAN (June 1, 2017)—The Global Health Innovative Technology Fund (GHIT Fund), which has been dedicated to leveraging Japanese expertise and capacity for health innovations to save lives in the world’s poorest countries, announced today that it has secured commitments of over US$200 million* to its replenishment for its next phase of work, allowing it to move the most advanced tools out of the lab, and into the hands of those who need them most.
GHIT’s funding partners, including the Government of Japan (GOJ), private companies, the Bill & Melinda Gates Foundation, and the Wellcome Trust have committed over US$200 million in a significant vote of confidence in the institution’s work. The new commitment for GHIT’s second phase is double the initial US$100 million investment GHIT received when it was created in 2013. The GOJ will contribute roughly half of the replenishment, with other partners splitting the remaining half…

PATH  [to 3 June 2017]
Announcement | May 30, 2017
Radboud University Medical Center, the Instituto de Medicina Molecular, and PATH’s Malaria Vaccine Initiative will collaborate on first-in-human study of a novel malaria vaccine approach
This early-stage study will test a new vaccine concept using a genetically modified parasite to induce protection
… The concept being tested is similar to that used by Edward Jenner to develop a vaccine against smallpox, the only disease affecting humans that has ever been eradicated. Jenner used cowpox—a similar but much less dangerous bovine version of the disease—to inoculate people against smallpox. In this clinical trial, based on data from earlier animal studies conducted by iMM Lisboa, the researchers will use a rodent version of the malaria-causing parasite (known as Plasmodium berghei) to determine if it can induce protection against infection by Plasmodium falciparum, the deadliest version of the parasite that infects humans.
In the study, a specific gene from P. falciparum known as the circumsporozoite protein (CS), will be inserted into the rodent parasite, resulting in a genetically modified version known as Pb(PfCS@UIS4). By inserting the gene for CS, the researchers hope to improve the potential of the modified rodent parasite to induce a protective response in healthy human volunteers.
“Bringing together the concept underlying the first vaccine ever developed, when Edward Jenner used the cowpox virus to immunize people against smallpox, with modern genetic manipulation tools, has resulted in a truly innovative approach to malaria vaccination,” said Miguel Prudêncio, who is leading the research team at iMM Lisboa…

2017.06.01   Report
GHIT’s 2016 Annual Report Published
Global Fund [to 3 June 2017];&country=
31 May 2017  News
UNHCR and Global Fund Strengthen Partnership to Expand Health Services to Refugees
GENEVA – UNHCR, the UN Refugee Agency, and the Global Fund to Fight AIDS, Tuberculosis and Malaria today signed an agreement intended to improve health services for refugees and other displaced communities. This new agreement will strengthen UNHCR’s humanitarian response – focusing on public health and education as well as emergency care.
“Our focus remains on working together to provide specialized health care for refugees and communities hosting them,” said Filippo Grandi, the UN High Commissioner for Refugees. “Our partnership ensures refugees have access to treatments for HIV, tuberculosis and malaria.”
Both agencies are already working together in Rwanda, where UNHCR is implementing a grant of US$2.09 million from the Global Fund to address health needs for Burundian refugees. Further discussions are also underway to expand joint activities in the Middle East and East Africa.
“We need to better connect pieces of the humanitarian response within the larger development continuum,” said Mark Dybul, Executive Director of the Global Fund. “This framework promotes innovation and advancing efforts that make sense and that work.”
EDCTP    [to 3 June 2017]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
29 May 2017
Leprosy Research Initiative and EDCTP in partnership to boost leprosy research
The Leprosy Research Initiative (LRI) and EDCTP created a partnership to boost leprosy-related research. They aim to leverage resources and pool funds to support clinical and implementation research in sub-Saharan Africa, particularly in relation to leprosy and neglected infectious diseases (NIDs) that are co-endemic with leprosy.
Wellcome Trust  [to 3 June 2017]
1 June 2017
Renewed commitment to Japanese global health fund
… Wellcome first supported GHIT in 2015 with a £3m grant for two research projects that aimed to find new treatments for malaria and tuberculosis. The new joint commitment for GHIT’s second phase is double the initial US$100m investment it received when it was created in 2013….

New insights into how Zika causes microcephaly
1 June 2017
… In a study, published in Science (opens in a new tab), the team showed that the Zika virus hijacks a human protein called Musashi-1 (MSI1), which is present in large amounts in neural stem cells. MSI1 allows Zika virus to replicate inside these cells and kill them. Neural stem cells eventually develop into a baby’s brain, so any loss of these cells can prevent a normal-sized brain from growing.

UK-EU research partnerships benefit patients across Europe
31 May 2017
A report commissioned by eight leading UK medical organisations highlights how partnerships between UK and EU medical researchers have increased the value of research, benefiting patients across Europe. This new research shows how the UK’s contribution to research throughout the EU has fostered and strengthened scientific cooperation in the following areas.

New genetic cause of childhood cancer found
29 May 2017
Scientists have identified a genetic mutation that causes a childhood kidney cancer called Wilms’ tumour. The research revealed how loss of control over the number of chromosomes in a cell can lead to cancer.

NIH  [to 3 June 2017]
June 2, 2017
Details of Lassa virus structure could inform development of vaccines, therapies
— Lassa virus can cause a hemorrhagic disease called Lassa fever and is endemic to western Africa.

May 30, 2017
NIH Scientists Find Real-Time Imaging in Mice a Promising Influenza Study Tool
— A non-invasive method to track and monitor viruses, bacteria, and various types of cells and genes.
PhRMA    [to 3 June 2017]
June 1, 2017
More than 240 immuno-oncology treatments in development to fight cancer
PhRMA, in partnership with the American Cancer Society Cancer Action Network (ACS CAN), announced today in a new report that there are more than 240 immuno-oncology medicines and vaccines in development to treat cancer.
UNAIDS  [to 3 June 2017]
Selected Press Releases & Updates
Report of the United Nations Secretary-General
The report of the United Nations Secretary-General on HIV is being presented in New York on 1 June 2017.
European Medicines Agency  [to 3 June 2017]
New action plan to support SMEs as drivers of pharmaceutical innovation
16 actions identified for implementation in 2017-2020
The European Medicines Agency (EMA) has published today an action plan for small and medium-sized enterprises (SMEs), which aims to foster innovation and support SMEs in the development of novel human and veterinary medicines.
SMEs are the backbone of Europe’s economy. They represent 99% of all businesses in the European Union (EU) and provide two-thirds of total private sector employment. In the pharmaceutical sector SMEs are a motor of innovation and play a major role in the development of new medicines…


IVI   [to 3 June 2017]
IVI co-hosts first Global Health Youth Leadership Forum at the Korean National Assembly
IVI and Representative Jeon Hye-sook, a member of the parliamentary Health and Welfare Committee, co-hosted the First Global Health Youth Leadership Forum at the National Assembly in Seoul on May 13. The forum, designed to inspire Korean youth to consider global health career paths, gathered about 150  college and middle- and high-school students. IVI Director General Dr. Jerome Kim and Rep. Jeon gave welcome speeches, and four experts including Prof. Kim Sun-young of Seoul National University School of Public Health; Dr. Beck Nam Seon, Director of Delivery at IVI; Ms. Choi Soon-young from World Vision; and Prof. Lee Byung-joo of Global Jobs, a private consulting firm, delivered lectures on topics that included the ‘Importance of health and development,’ ‘Cooperation and partnership in international health,’ and ‘Employment at international organizations.’…


Industry Watch
:: European Commission Approves Pfizer’s TRUMENBA® to Help Prevent Meningococcal Group B Disease in Adolescents and Adults
   Meningococcal Group B (MenB) is Responsible for 60 Percent of Meningococcal Disease Cases in Adolescents and Young Adults in Europe1
   TRUMENBA Approved in Europe with Option for a Two- or Three-Dose Schedule
May 30, 2017
:: NovaDigm Therapeutics Awarded $6 Million by U.S. Department of Defense to Conduct a Phase 2a Staphylococcus aureus Vaccine Trial
Assessing the Impact of NDV-3A Vaccine on S. aureus Colonization in a High Risk Population of Military Trainees
June 02, 2017